TG Therapeutics
TGTX
81 hedge funds and large institutions have $250M invested in TG Therapeutics in 2016 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 35 increasing their positions, 20 reducing their positions, and 15 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 20
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less funds holding
Funds holding: 87 → 81 (-6)
22% less capital invested
Capital invested by funds: $320M → $250M (-$71M)
40% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 15
73% less call options, than puts
Call options by funds: $338K | Put options by funds: $1.25M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$15M |
| 2 |
VAM
Visium Asset Management
New York
|
+$4.59M |
| 3 |
UBS AM
Chicago,
Illinois
|
+$4.08M |
| 4 |
BM
Bridger Management
New York
|
+$2.43M |
| 5 |
TRSOTSOK
Teachers Retirement System of the State of Kentucky
Frankfort,
Kentucky
|
+$1.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.07M |
| 2 |
Millennium Management
New York
|
-$1.89M |
| 3 |
CCI
Columbus Circle Investors
|
-$811K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$554K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$443K |
TGTX Hedge Fund Activity: Q1 2016 in Review
81 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q1 2016, worth a combined $250M — down 22% from $320M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of TGTX and 9 opened new positions — a net loss of 6 holders — while 20 trimmed existing stakes and 35 added.
The largest buyer was RA Capital Management, adding an estimated $15M. The largest seller was Fidelity Investments, cutting an estimated $2.07M.
- 81 institutional investors held TG Therapeutics (TGTX) as of Q1 2016, down from 87 in Q4 2015.
- Funds reported $250M of TG Therapeutics stock for Q1 2016, down 22% quarter-over-quarter.
- 9 funds opened new TG Therapeutics positions in Q1 2016 and 15 closed out, a net change of -6 holders.
- The largest TG Therapeutics buyer in Q1 2016 was RA Capital Management, an estimated $15M added.
- The largest TG Therapeutics seller in Q1 2016 was Fidelity Investments, an estimated $2.07M sold.
Based on aggregated 13F filings for Q1 2016.